India Inc India Inc: Monday, 12 March 2018 05:26

Centaur Pharma partners with Kibow Biotech

 

Centaur Pharmaceuticals and Kibow Biotech USA announced a strategic long-term alliance to market Renadyl in India. Centaur will initially import and market the product in India, and will eventually manufacture and market with technical inputs from Kibow Biotech.

Dr Natrajan Ranganathan, Founder and Managing Director, Kibow Biotech, said: "We can together offer the benefits of my 20 years of research to millions of Indian patients suffering from Chronic Kidney Disease (CKD) and make their lives better. Kibow also has an interesting research pipeline which we hope to bring to India for the benefit of Indian patients."

S.D. Sawant, Chairman and MD, Centaur Pharmaceuticals, said: "Kibow has a strong research infrastructure and expertise in modulating gut micro biome. Through this alliance, Centaur will leverage Kibow's research expertise and its own strong manufacturing and marketing skills to offer hope in the form of Renadyl to patients in India suffering from CKD. We are happy to announce this alliance in the backdrop of World Kidney Day and World Women's Day coming up on March 8."

A globally patented product, Renadyl, is an effective kidney health therapy, targeted towards CKD patients, particularly those in Stage III/ IV (pre-dialysis). It is clinically proven to reduce nitrogenous waste and delay the need for dialysis and also provides improved quality of life for Stage V patients on dialysis.

India Investment Journal’ has in-depth coverage on related topics.

Login to post comment
Get in Touch
This email address is being protected from spambots. You need JavaScript enabled to view it.

Array ( [format] => html [Itemid] => 148 [option] => com_k2 [view] => item [task] => 7165:centaur-pharma-partners-with-kibow-biotech [id] => 7165:centaur-pharma-partners-with-kibow-biotech )